Fiche société
TriGemX Bio, Inc.
Traitements, essais et publications liés.
Traitements7programmes
Essais4liés
Publications0liées
SourceDBlocale
Traitements
7| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| ElismetrepThis is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks. | Migraine | Phase 3 | À vérifier | United States | À vérifier |
| K-645 10 mgThis is a multicenter, randomized, double-blind, placebo-controlled, 3-period crossover study to evaluate the safety, tolerability, and efficacy of two dose levels of K-645 in the treatment of patients with acute migraine. | Migraine | Phase 2 | À vérifier | United States | À vérifier |
| K-645 100 mgThis is a multicenter, randomized, double-blind, placebo-controlled, 3-period crossover study to evaluate the safety, tolerability, and efficacy of two dose levels of K-645 in the treatment of patients with acute migraine. | Migraine | Phase 2 | À vérifier | United States | À vérifier |
| ElismetrepThis is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks. | Migraine | Phase 3 | À vérifier | United States | À vérifier |
| ElismetrepThis is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks. | Migraine | Phase 3 | À vérifier | United States | À vérifier |
| ElismetrepThis is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks. | Migraine | Phase 3 | À vérifier | United States | À vérifier |
| K-645 100 mgThis is a multicenter, randomized, double-blind, placebo-controlled, 3-period crossover study to evaluate the safety, tolerability, and efficacy of two dose levels of K-645 in the treatment of patients with acute migraine. | Migraine | Phase 2 | À vérifier | United States | À vérifier |
Essais cliniques
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| K-645 100 mg | Migraine | Phase 2 | NCT07116499 | A Study of K-645 in the Treatment of Multiple Migraine Attacks | TERMINATED |
| Elismetrep | Migraine | Phase 3 | NCT07816367 | A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | RECRUITING |
| Elismetrep | Migraine | Phase 3 | NCT07645924 | A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | RECRUITING |
| Elismetrep | Migraine | Phase 3 | NCT07674654 | A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine | RECRUITING |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||